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Introduction
Extracellular matrix (ECM) degradation by proteases occurs
at many stages of malignant progression, including local
invasion, angiogenesis and intravasation and extravasation of
tumors during metastasis (Liotta et al., 1983; McCawley and
Matrisian, 2001). Proteases of the plasminogen-activator
system, matrix metalloproteinases (MMPs) and cysteine
proteases such as cathepsin B have all been implicated in these
invasive processes (Koblinski et al., 2000; Mignatti et al., 1986;
Sloane et al., 2005). Localization of proteases to tumor-cell
surfaces and secretion into the extracellular milieu gives these
enzymes access to the ECM (Cavallo-Medved and Sloane,
2003; Koblinski et al., 2000). Evidence also shows the
involvement of proteases in the intracellular degradation of
ECM proteins (Everts et al., 1996; Kjoller et al., 2004; Sameni
et al., 2000; Sameni et al., 2003).
In colorectal carcinomas, increased expression and activity
of proteases contribute to degradation events during tumor
invasion. Indeed, high levels of the lysosomal cysteine-
protease cathepsin B in colon cancer patients are predictive of
shorter overall survival (Campo et al., 1994). Furthermore,
translocation of cathepsin B from the apical region of the cells
to the basal plasma membranes parallels malignant progression
of colon cancer, occurring in late adenomas and early
carcinomas (Campo et al., 1994). The cathepsin B associated
with the basal plasma membrane of human colon tumors is
active (Hazen et al., 2000). Increases in expression of cathepsin
B and translocation of active cathepsin B to the basal
membrane are also observed during the progression of
adenomas in Min mice (Marten et al., 2002), a model for
familial adenomatous polyposis in humans (for a review, see
Dove et al., 1995). Membrane-associated cathepsin B can be
isolated from a range of cancer cells (Rozhin et al., 1987;
Rozhin et al., 1994), and activities can be assayed on the
surface of living cells in culture (Linebaugh et al., 1999),
suggesting a functional role for this enzyme on tumor-cell
surfaces.
Elevated levels of uPA (urokinase plasminogen activator)
and its receptor, uPAR, have been associated with a negative
prognosis (Ganesh et al., 1994) and distant metastases (Yang
et al., 2000) of colorectal cancer. uPAR has also been localized
to the invasive front of colon adenocarcinomas (Pyke et al.,
1991). Antisense downregulation of uPAR expression both
reduced receptor-bound uPA activities and ECM degradation
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(pro-uPA) localize to the caveolae of HCT 116 human
colorectal carcinoma cells, an association mediated by
active K-RAS. In this study, we established a stable HCT
116 cell line with a gene encoding antisense caveolin-1 (AS-
cav-1) to examine the effects of caveolin-1, the main
structural protein of caveolae, on the expression and
localization of cathepsin B and pro-uPA, and their cell-
surface receptors p11 and uPA receptor (uPAR),
respectively. AS-cav-1 HCT 116 cells secreted less
procathepsin B than control (empty vector) cells as
measured by immunoblotting and pepsin activation of the
proenzyme. Expression and secretion of pro-uPA was also
downregulated in AS-cav-1 HCT 116 cells. Localization of
cathepsin B and pro-uPA to caveolae was reduced in AS-
cav-1 HCT 116 cells, and these cells expressed less total and
caveolae-associated p11 and uPAR compared with control
cells. Previous studies have shown that uPAR forms a
complex with caveolin-1 and β1-integrin, and we here show
that downregulation of caveolin-1 also suppressed the
localization of β1-integrin to caveolae of these cells. Finally,
downregulation of caveolin-1 in HCT 116 cells inhibited
degradation of the extracellular matrix protein collagen IV
and the invasion of these cells through Matrigel. Based on
these results, we hypothesize that caveolin-1 affects the
expression and localization of cathepsin B and pro-uPA,
and their receptors, thereby mediating cell-surface
proteolytic events associated with invasion of colon cancer
cells.
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in vitro, and suppressed colon cancer metastasis in an in vivo
nude mouse model (Wang et al., 2001). A functional role for
uPA is to convert plasminogen to plasmin, a serine protease
capable of degrading key ECM components and activating
other zymogen proteases such as pro-MMP-9 and pro-MMP-
3 (Davis et al., 2001; Hahn-Dantona et al., 1999; Ramos-
DeSimone et al., 1999). Correlations have been made between
expression of individual MMPs (e.g. MMP-1 and MMP-13)
(Leeman et al., 2002; Murray et al., 1996) and poor prognosis
in colorectal cancer (Leeman et al., 2003). In colorectal tumor
tissues, the expression and activities of MMP-1, MMP-2,
MMP-3 and MMP-9 are upregulated compared with normal
mucosal tissue (Baker and Leaper, 2003). Moreover, the level
of tissue inhibitor of metalloproteinase-2 (TIMP-2) was
significantly decreased in these colorectal tumor tissues (Baker
and Leaper, 2003). Hence, this suggests that, in colon cancer,
the balance between proteases and inhibitors, and the complex
interactions between protease systems are important to
tumorigenesis.
Many proteases implicated in the progression and invasion
of colorectal tumors have been found to associate with
caveolae (Cavallo-Medved and Sloane, 2003), a region of the
plasma membrane involved in endocytosis, cholesterol
transport and cell signaling events (for reviews, see Anderson,
1998; Williams and Lisanti, 2004). Our laboratory recently
reported the localization of cathepsin B to caveolae of HCT
116 human colorectal carcinoma cells (Cavallo-Medved et al.,
2003). HCT 116 cells contain a mutant K-ras gene, disruption
of which by homologous recombination (Shirasawa et al.,
1993) led to a decrease in cathepsin-B trafficking to caveolae
and a decrease in pericellular (membrane-associated and
secreted) activity of the enzyme (Cavallo-Medved et al., 2003).
Localization of active cathepsin B and p11 [the light chain of
the annexin II tetramer (AIIt) and a cathepsin-B-binding
protein (Mai et al., 2000)] to caveolae is intriguing because
cathepsin B activates soluble and membrane-bound pro-uPA
(Ikeda et al., 2000; Kobayashi et al., 1991) and p11 is involved
in the binding and activation of plasminogen (Zhang et al.,
2004). The loss of mutant K-ras in HCT 116 cells also
suppressed the localization of uPA and uPAR to caveolae of
these cells (Cavallo-Medved et al., 2003). Several MMPs, such
as MMP-2 and membrane-type-1 MMP (MT1-MMP), have
been localized to caveolae of glioblastomas, fibrosarcomas and
endothelial cells, as have TIMP-2 and αvβ3 integrin, an
integrin that acts as a receptor for MMP-2 (Annabi et al., 2001;
Puyraimond et al., 2001). In migrating human endothelial cells,
caveolae have been shown to mediate trafficking, localization
and activity of MT1-MMP (Galvez et al., 2004). Thus, these
data support a role for caveolae in cell-surface proteolysis.
In confocal assays using human colorectal-carcinoma cells,
cathepsin B and MMPs participate in the extracellular
degradation of type-IV collagen, implicating these enzymes in
cell-surface proteolytic events (Sameni et al., 2003). We
hypothesize that caveolae act as sites for the clustering of cell-
surface proteases, thereby facilitating the initiation of
proteolytic events involved in cell migration and tumor
invasion. Here, we demonstrate a positive correlation between
caveolin-1 and the expression, localization and activities of the
caveolae-associated proteases cathepsin B and uPA, and their
cell-surface receptors p11 and uPAR, respectively, in human
colorectal-carcinoma cells. Furthermore, we show that
downregulation of caveolin-1 expression reduces pericellular
and intracellular degradation of the ECM protein collagen IV
and the invasion of these cells through Matrigel.
Materials and Methods
Materials
Dulbecco’s minimal Eagle’s medium (DMEM), bovine serum
albumin (BSA), antibiotics, DNA (salmon sperm), octylglucoside, 2-
[N-morpholino]ethanesulfonic acid (MES) and all other chemicals,
unless otherwise stated, were from Sigma (St Louis, MO). Fetal
bovine serum (FBS), fetal calf serum (FCS) and LipofectAmine were
from Invitrogen Life Technologies. Polyclonal anti-caveolin (610059)
and monoclonal anti-p11 (mAb 148) antibodies were purchased
from Transduction Laboratories (Lexington, KY). Polyclonal anti-
cathepsin-B antibodies (Moin et al., 1992) were produced and
characterized in our laboratory. Polyclonal anti-uPA and polyclonal
anti-uPAR antibodies were a kind gift from G. Hoyer-Hansen (The
Finsen Center, Copenhagen, Denmark). Polyclonal anti-MMP-2
(AB19145), polyclonal anti-MMP-9 (AB16996), polyclonal anti-
MT1-MMP (AB8345) and monoclonal anti-β1-integrin (MAB2247)
antibodies were from Chemicon (Temecula, CA). Horseradish-
peroxidase-labeled goat anti-rabbit and goat anti-mouse IgG, and
micro-bicinchoninic acid (BCA) reagents were from Pierce
(Rockford, IL). Texas-Red-conjugated affinity-purified donkey anti-
rabbit IgG were from Jackson ImmunoResearch (West Grove, PA).
Quenched fluorescent type-IV collagen (DQ-collagen IV), SYBR
Green I nucleic-acid stain and SlowFade antifade reagent were from
Molecular Probes (Eugene, OR). Matrigel was from BD Biosciences
(Bedford, MA). Caveolin-encoding cDNA was from American Type
Culture Collection (Rockville, MD). PCR primers were from
Integrated DNA Technologies (Coralville, IA). Vectors were from
Stratagene (La Jolla, CA). Diff Quik stain set was from Dade Behring
(Newark, DE). Acrylamide and nitrocellulose membranes were
from BioRad (Hercules, CA). Prestained protein markers and
chemiluminescent western-blotting detection kits were from
Amersham Pharmacia Biotech (Piscataway, NJ). Benzyloxycarbonyl-
L-arginyl-L-arginine-4-methyl-7-coumarylamide (Z-Arg-Arg-
NHMec) was from Bachem (Torrance, CA). Amicon Ultra-4 10 K
centrifugal filters were from Millipore (Bedford, CA). Polycarbonate
filters (polyvinylpyrrolidone, 12 µm pore, 13 mm diameter) were from
Poretics (Livermore, CA). Finder grids were from Ted Pella (Redding,
CA).
Cell culture
HCT 116 and NIH 3T3 cells were from the American Type Culture
Collection (Rockville, MD) and grown in DMEM with glutamine, 4.5
g l–1 glucose, antibiotics (penicillin and streptomycin) and 10% (v/v)
FBS (for HCT 116 cells) or 5% (v/v) FCS (for NIH 3T3 cells) in 5%
CO2 in a humidified atmosphere at 37°C.
Construction of caveolin-1 antisense vector
The cDNA fragment encoding human caveolin-1 was amplified by
PCR using a human caveolin-1-encoding cDNA plasmid (ATCC,
Manassas, VA) as a template. The primer pair used for the
amplification was: 5′ primer, 5′-GCCGCCGAGCTCTATTTCT-
TTCTGCAAGTTGA-3′ (containing the underlined SacI site); 3′
primer, 5′-GCCGCCCCCGGGATGTCTGGGGGCAAATACGT-3′
(containing the underlined SmaI site). The amplified cDNA fragment
in the antisense orientation was subsequently cloned into the
corresponding multiple cloning sites of the pIRES-hrGFP-1a vector
to form the pAnti-caveolin-1-IRES-hrGFP-1a vector. The pAnti-
caveolin-1-IRES-hrGFP-1a vector and the control vector pIRES-
hrGFP-1a were then individually recombined with a pExchange-Puro
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recombinant vector according to manufacturer’s instructions. The
identities and orientations of the resulting pAnti-caveolin-1-IRES-
hrGFP-1a-puro vector and pIRES-hrGFP-1a-puro vector were
confirmed by DNA sequencing.
Establishment of stable caveolin-1 antisense HCT 116 cell
lines
Parental HCT 116 cells grown to 60% confluence were transfected
with antisense caveolin-1 (AS-cav-1) or empty (control) pIRES-
hrGFP-1a recombinant vectors using LipofectAmine reagent
according to the manufacturer’s instructions. Transfected cultures
were selected with puromycin (0.5 µg ml–1) for 15 days at 37°C and
antibiotic-resistant colonies were picked and grown under selective
conditions for further analysis.
Semiquantitative reverse-transcription PCR
For reverse-transcription PCR (RT-PCR), total RNA was isolated from
cells transfected with mock or antisense vectors using a RNeasy Mini
Kit (QIAGEN, Valencia, CA) and reverse transcribed. 1 µg total RNA
was annealed with 0.5 µg oligo-dT15 and reverse transcribed in a 20
µl volume containing 1 reverse-transcription buffer (Promega,
Madison, WI), 0.1 mg ml–1 BSA, 40 U RNAsin (Promega, Madison,
WI), 1 mM dNTPs and 200 U mouse Moloney leukemia virus
(MMLV) reverse transcriptase (Promega, Madison, WI) at 37°C for
120 minutes. A 5 µl aliquot was used for subsequent PCR reactions
using the PCR Master Mix from Promega (Madison, WI). For β2-
microglobulin (150-bp product), p11 (317-bp product), cathepsin B
(1044-bp product) and caveolin-1 (557-bp product), the amplification
conditions were as follows: 25 cycles of 94°C for 30 seconds, 60°C
for 30 seconds, 72°C for 1 minute, followed by a final 10-minute
extension at 72°C. PCR products were resolved on a 1.2% agarose gel
stained with ethidium bromide. The primer sequences were as
follows: β2-microglobulin forward, 5′-TTAGCTGTGCTCGCGCT-
ACTCTCTC-3′; β2-microglobulin reverse, 5′-GTCGGATGGATGA-
AACCCAGACACA-3′; p11 forward, 5′-GGCGGCGGATCCATG-
CCATCTCAAATGGAACA-3′; p11 reverse, 5′-GGCGGCGAAT-




AAATACGT-3′; caveolin-1 reverse, 5′-GCCGCCGAGCTCTATTT-
CTTTCTGCAAGTTGA-3′.
Preparation of cellular extracts
Cells were washed twice with cold PBS and solubilized in lysis buffer
(10 mM Tris, pH 7.5, 50 mM NaCl, 1% Triton X-100, 60 mM
octylglucoside) on ice. Cell extracts were then passed ten times
through a syringe with a 20-gauge needle and centrifuged for 5
minutes at 10,000 g at 4°C. The cell-homogenate supernatant was
recovered and protein concentrations were quantified using micro-
BCA reagents according to the manufacturer’s instructions. Equal
protein aliquots of each sample were analysed by SDS-PAGE and
immunoblotting.
SDS-PAGE and immunoblot analysis
Samples were separated by SDS-PAGE (10%, 12% or 15%
acrylamide) and transferred onto nitrocellulose membranes.
Immunoblotting was performed with primary antibodies against
cathepsin B (1:4000), caveolin (1:5000), p11 (1:5000), uPA (5 µg
ml–1), uPAR (5 µg ml–1), β1-integrin (1:1000), MMP-2 (1:1000),
MMP-9 (1:1000) and MT1-MMP (1:1000), and secondary antibodies
conjugated with horseradish peroxidase (1:10,000) in TBS wash
buffer (20 mM Tris, pH 7.5, 0.5 M NaCl) containing 0.5% Tween-20
and 5% (w/v) non-fat dried milk. After washing, specifically bound
antibodies were detected by enhanced chemiluminescence according
to the manufacturer’s instructions (Amersham Pharmacia Biotech).
Quantification and analysis of the bands were performed using a
Luminescent Image Analyzer LAS-1000 Plus (Fujifilm).
Preparation of caveolae-enriched membrane fractions
Preparation of caveolae-enriched membrane fractions was performed
as previously described (Smart et al., 1995; Song et al., 1996). Briefly,
cells from four 100 mm dishes were washed twice with cold (4°C)
PBS and then scraped into 2 ml 500 mM sodium carbonate, pH 11.0.
Cells were homogenized on ice by ten strokes in a loose-fitting
Dounce homogenizer. The lysates were then sonicated on ice in a 50
W Ultrasonicator three times for 20 seconds each and adjusted to
equal protein concentrations. The homogenates were adjusted to 45%
sucrose by the addition of 2 ml 90% (w/v) sucrose prepared in MES-
buffered saline (25 mM MES, pH 6.5, 0.15 m NaCl) and placed on
the bottom of a 12 ml ultracentrifuge tube. The homogenate was
overlaid with a 5-35% discontinuous sucrose gradient by adding 4 ml
35% (w/v) sucrose (in MES-buffered saline containing 250 mM
sodium carbonate) and 4 ml 5% (w/v) sucrose (in MES-buffered
saline containing 250 mM sodium carbonate) and centrifuged at
185,000 g for 18-20 h in a SW41 rotor (Beckman Instruments) at 4°C.
A light-scattering band was observed at the 5-35% sucrose interface.
From the top of the gradient, 1 ml fractions were collected to yield a
total of 12 fractions. Equal volume aliquots from each gradient
fraction were analysed by SDS-PAGE and immunoblotting.
Immunocytochemical staining and confocal microscopy
Cells were grown on glass coverslips to 80% confluence and
intracellular staining was carried out at room temperature using
saponin-permeabilized cells as previously described (Sameni et al.,
2000). Primary antibodies used were rabbit anti-human caveolin (5 µg
ml–1) and secondary antibodies used were Texas-Red-conjugated
affinity-purified donkey anti-mouse IgG (20 mg ml–1). Coverslips
were mounted upside-down with Slow-Fade antifade reagent on glass
slides and the cells were observed on a Zeiss LSM 310 microscope
in confocal mode.
Cathepsin-B activity assay
Cathepsin-B activity assays on cells and media were performed as
previously described (Koblinski et al., 2002; Linebaugh et al., 1999).
Briefly, cells were serum starved overnight and media were collected,
centrifuged to remove whole cells and concentrated using Amicon
Ultra-4 10 K centrifugal filters. Cells were solubilized in lysis buffer
(250 mM sucrose, 25 mM MES, pH 7.5, 1 mM EDTA, 0.1% Triton
X-100) and sonicated on ice in a 50 W Ultrasonicator three times for
10 seconds each. To measure intracellular cathepsin-B activity, 50 µl
cell lysates were incubated with 300 µl activator buffer (5 mM EDTA,
10 mM dithiothreitol, pH 5.2) for 15 minutes at 37°C. In a 96-well
flat-bottomed black microtiter plate, 100 µl cell-lysate/activator-buffer
mixture was added to 200 µl assay buffer [Hank’s balanced salt
solution lacking sodium bicarbonate and phenol red, and containing
0.6 mM CaCl2, 0.6 mM MgCl2, 25 mM piperazine-N,N′-bis(2-
ethanesulfonic acid) (disodium salt), pH 7.3] containing 150 µM Z-
Arg-Arg-NHMec substrate. Fluorescence was measured in triplicate
at 1-minute intervals for 30 minutes using a Tecan Spectrafluor Plus
plate reader with excitation at 360 nm and emission at 465 nm. To
measure latent cathepsin-B activity in media samples, 50 µl
concentrated medium was incubated for 15 minutes at 37°C in 0.1 M
formate, pH 3.2, containing 0.4 mg ml–1 pepsin. Then, 100 µl 20 mM
dithiothreitol (prepared in 0.2 M sodium phosphate buffer, pH 6.8,
containing 4 mM EDTA, 0.1% Triton X-100) was added to each












Z-Arg-Arg-NHMec substrate was added to each sample. 120 µl
aliquots of the reaction mixture were added to a 96-well flat-bottomed
black microtiter plate and fluorescence was read in triplicate at 1-
minute intervals for 30 minutes with excitation at 360 nm and
emission at 465 nm. DNA assays were performed on each sample and
cathepsin-B activity was recorded as pmoles min–1 (µg DNA)–1.
Statistical significance was determined by a two-tailed Student’s t test
with assumed equal variance. In the figures, asterisks represent a P
value less than 0.05 and double asterisks represent a P value less than
0.01.
DNA assay
5 µl cell lysates were mixed with 195 µl DNA buffer (10 mM Tris-
HCl, pH 7.0, 100 mM NaCl, 10 mM EDTA) containing 2 µl SYBR
Green I nucleic-acid stain in a 96-well flat-bottomed black microtiter
plate and incubated for 10 minutes at room temperature in the dark.
Fluorescence was measured with excitation at 485 nm and emission
at 535 nm, and sample DNA concentrations were calculated against
a standard curve of salmon-sperm DNA.
Live-cell proteolysis assay
Proteolysis by live cells was assessed as previously described (Sameni
et al., 2003). Briefly, glass coverslips were coated with 50 µl 12 mg
ml–1 Matrigel containing 25 µg ml–1 quenched fluorescent substrate
DQ-collagen IV (Molecular Probes) and incubated for 10 minutes at
37°C to solidify. Cells (2104) were seeded onto each coated
coverslip and incubated for 60 minutes at 37°C. Complete medium
(DMEM plus 10% FBS) was added to the cells and incubated for 48
hours at 37°C. After 48 hours, proteolysis of DQ-collagen IV (green
fluorescence) by live cells was observed using a Zeiss LSM 310
confocal microscope with a 40 water-immersion objective. Levels
of proteolysis were quantified using Metamorph Software (Universal
Imaging).
Invasion assay
Invasion assays were performed using Boyden chambers as previously
described (Demchik et al., 1999; Sameni et al., 2003). Briefly,
polycarbonate filters (12 µm) were coated with 1% (w/v) gelatin and
dried overnight. Matrigel (35 µg) was then added to each filter and
dried for 4 hours. The coated filters were placed in Boyden chambers
and conditioned medium from log-phase NIH 3T3 cells incubated
overnight in DMEM supplemented with 4.5 g l–1 glucose and 2% FCS
was added to the lower compartment of the chambers as a
chemoattractant. Cells (3104) in 200 µl DMEM with 4.5 g l–1
glucose and 0.1% BSA were placed on top of the coated filters. Cells
were incubated at 37°C for 24 hours and allowed to invade through
the Matrigel-coated filters. After 24 hours, the filters were removed
from the chambers and the cells were fixed and stained using the Diff-
Quik stain set. Cells that did not invade through the Matrigel-coated
filters were removed using a cotton swab and cells that did invade
were counted three times by two independent counters on a Nikon
TMS microscope with a 10 objective using finder grids.
Results
Downregulation of caveolin-1 in HCT 116 cells
HCT 116, the human colorectal cell line used for these studies,
contains a point mutation that activates one of the K-ras alleles
making them tumorigenic (Shirasawa et al., 1993). Our
previous studies revealed that the mutant K-ras in HCT 116
Journal of Cell Science 118 (7)
Fig. 1. Establishment of a stable
antisense caveolin-1 HCT 116
human colorectal-carcinoma cell
line. HCT 116 cells were
transfected with either empty vector
(control) or vector containing
caveolin-1-encoding cDNA in the
antisense orientation (AS-cav-1)
and stable clones were selected in
the presence of 0.5 mg ml–1
puromycin for 15 days.
(A) Parental, control and AS-cav-1
HCT 116 cells were solubilized in
lysis buffer containing 1% Triton
X-100, 60 mM octylglucoside. 20
µg protein were analysed by SDS-
PAGE and immunoblotted with
antibodies to human caveolin-1 and
human β-actin in order to verify
equal loading. Immunoblots are
shown in triplicate and are
representative of at least three
experiments. (B) 1 µl total RNA
isolated from control and AS-cav-1
HCT 116 cells was subjected to reverse transcription followed by PCR using primer sequences to caveolin-1 and β2-microglobulin (as a control).
PCR products were resolved on a 1.2% agarose gel stained with ethidium bromide. (C) Equal amounts of protein for HCT 116, control and AS-
cav-1 cells were subjected to subcellular fractionation on a sucrose gradient after homogenization in sodium carbonate buffer, pH 11.0. Fractions
were collected from the top of the gradient and equal volume aliquots of fractions 2-11 were analysed by SDS-PAGE and immunoblotted with
anti-human caveolin-1 antibodies. Immunoblots are representative of at least three experiments. (D) Staining was performed on control and AS-
cav-1 HCT 116 cells grown on glass coverslips. Cells were incubated in the presence of saponin with primary antibodies to rabbit anti-human
caveolin-1 IgG and then incubated with Texas-Red-conjugated affinity-purified donkey anti-rabbit IgG plus normal donkey serum. The cells were
observed with a Zeiss LSM 310 microscope in confocal mode at a magnification of 630 under oil immersion. Staining for caveolin-1 is shown
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cells mediates localization of cathepsin B specifically to the
caveolae on the surface of these cells (Cavallo-Medved et al.,
2003). In the present study, we used HCT 116 cells to explore
the effects of caveolin-1 expression, a main structural protein
of caveolae, on caveolae-associated proteases. HCT 116 cells
were transfected with either pIRES-hrGFP-1a expression
vector containing caveolin-1-encoding cDNA in the antisense
orientation or the empty vector alone. Clones were grown in
selection medium containing 0.5 µg ml–1 puromycin and each
clone was tested by immunoblotting for the production of
caveolin-1. In Fig. 1A, the production of caveolin-1 is
illustrated for the parental HCT 116 cells, a selected HCT 116
clone transfected with the empty vector (control) and a selected
HCT 116 clone transfected with the vector containing
caveolin-1-encoding cDNA in the antisense orientation (AS-
cav-1). Caveolin-1 expression in control cells was comparable
to that observed in parental HCT 116 cells but caveolin-1
production in AS-cav-1 cells was downregulated ~80%
compared with both the parental and control HCT 116 cells.
Furthermore, we performed RT-PCR to show a downregulation
of caveolin-1 RNA in AS-cav-1 HCT 116 cells compared with
control cells (Fig. 1B).
To isolate caveolae and their associated proteins from HCT
116 colon-carcinoma cells, we used a well-established protocol
(Song et al., 1996) based on the insolubility of caveolae to
carbonate extraction and their specific buoyant density in
equilibrium sucrose gradients. Fig. 1C illustrates the
distribution pattern of caveolin-1 in fractions 2-11; fraction 1
is not included here or in subsequent figures because our
previous studies revealed no detectable proteins in this fraction
(Cavallo-Medved et al., 2003). Fractionation of parental,
control and AS-cav-1 HCT 116 cells verified that the bulk of
caveolin-1 (seen as α and β isoforms) was isolated in low-
density fractions 4-6, hereafter designated as the caveolae
fractions (Fig. 1C). There was a dramatic reduction in the
expression of caveolin-1 in the caveolae fractions of AS-cav-1
cells compared with both the parental and the control HCT 116
cells. The levels of caveolin-1 in the caveolae fractions of
control HCT 116 cells were comparable to those found in the
parental HCT 116 cells and thus, hereafter, we chose to use
control HCT 116 cells for comparison with the AS-cav-1 cells.
To illustrate further the difference in caveolin-1 expression
between control and AS-cav-1 HCT 116 cells, we performed
immunocytochemistry on these cells (Fig. 1D). Staining for
caveolin-1 in saponin-permeabilized control cells showed
discrete red rings adjacent to the cell membrane, a pattern
similar to that previously observed in parental HCT 116 cells
(Cavallo-Medved et al., 2003). Staining for caveolin-1 in AS-
cav-1 cells was shown to be substantially less than that
observed in control cells and no discrete rings were detected
around the cell surface. The loss of caveolin-1 in AS-cav-1
cells might suggest a reduction in the number of caveolae
formed at the surface of these cells, as previously reported by
others (Cho et al., 2003; Griffoni et al., 2000).
Caveolin-1 expression alters cathepsin-B secretion
Previous studies from our laboratory have identified cathepsin
B in the caveolae of HCT 116 cells (Cavallo-Medved et al.,
2003). Furthermore, we established a positive correlation for
active K-ras, the expression of caveolin-1 and the localization
of cathepsin B in the caveolae of these cells. In the present
study, we examined the expression levels of cathepsin-B RNA
and protein in the cell lysates of control versus AS-cav-1 HCT
116 cells. RT-PCR results showed no differences in the RNA
levels of cathepsin B between AS-cav-1 HCT 116 cells and
controls (Fig. 2A). Immunoblotting revealed that, in both
cell lines, intracellular cathepsin-B protein was found
Fig. 2. Differences in the expression, localization and activity of
cathepsin B in AS-cav-1 HCT 116 cells. (A) 1 µl total RNA isolated
from control and AS-cav-1 HCT 116 cells was subjected to reverse
transcription followed by PCR using primer sequences to cathepsin
B and β2-microglobulin (as a control). PCR products were resolved
on a 1.2% agarose gel stained with ethidium bromide.
(B) Conditioned media from control and AS-cav-1 HCT 116 cells
were collected and the cells were solubilized in lysis buffer
containing 0.1% Triton X-100. Media and cell lysates (40 µg protein)
were analysed by SDS-PAGE and immunoblotted with anti-human-
cathepsin-B antibodies. Immunoblots are representative of at least
three experiments. (C) Conditioned media and cell lysates from
control and AS-cav-1 HCT 116 cells were assayed for cathepsin-B
activity. Intracellular (cell lysates) and extracellular (media)
cathepsin-B activities were measured against Z-Arg-Arg-NHMec
substrate and activity was expressed as pmoles min–1 (µg DNA)–1.
The graphs are representative of at least three experiments and
presented as means ± standard deviation (s.d.). **P<0.01. (D) Equal
amounts of protein for control and AS-cav-1 HCT 116 cells were
subjected to subcellular fractionation on a sucrose gradient after
homogenization in sodium-carbonate buffer, pH 11.0. Fractions were
collected from the top of the gradient and equal-volume aliquots of
fractions 2-11 were analysed by SDS-PAGE and immunoblotted with
anti-human-cathepsin-B antibody. Immunoblots are representative of












predominantly as the two active forms: the mature single chain
(31 kDa) isoform and the heavy chain (25/26 kDa) of the two
mature double-chain isoforms. Interestingly, the expression of
31 kDa cathepsin B was reduced by 50% in the AS-cav-1 cells
compared with the control cells, and the smaller double chain
isoform was not present in the control cells (Fig. 2B). We also
compared the levels of cathepsin B secreted from these cells
and found that AS-cav-1 cells secreted 50% less procathepsin
B (the predominant isoform of cathepsin B secreted by tumor
cells) than did control cells (Fig. 2B). Differences in the
expression of cathepsin B isoforms suggest that trafficking of
the enzyme is different in AS-cav-1 cells and control cells.
Specifically, the expression level of caveolin-1 appears to affect
secretion of cathepsin B from these colon cancer cells.
Trafficking of cathepsin B in HCT 116 cells was further
investigated by comparing the intracellular and extracellular
activity levels of cathepsin B in control and AS-cav-1 cells. In
these assays, cathepsin-B activity was measured against the Z-
Arg-Arg-NHMec substrate under conditions highly selective
for cleavage by cathepsin B (Linebaugh et al., 1999); cleavage
was completely inhibited by 10 µM CA074 (data not shown),
a highly selective cathepsin-B inhibitor (Murata et al., 1991).
The results show that there was a twofold increase in
intracellular cathepsin-B activity in AS-cav-1 cells compared
with the control cells (Fig. 2C), a trend that coincides with
levels of production of cathepsin-B protein (Fig. 2B). To
measure the activity of secreted procathepsin B, the medium
samples were preincubated with pepsin to activate the
proenzyme before conducting the activity assays. The data
revealed that pepsin-activated procathepsin-B activity in the
medium from AS-cav-1 cells was approximately half that
measured in the medium from control cells (Fig. 2C),
coinciding with the 50% decrease in procathepsin-B protein
secreted from AS-cav-1 versus control cells (Fig. 2B). These
results support the hypothesis that caveolin-1 expression
regulates the trafficking and secretion of cathepsin B in HCT
116 cells.
Downregulation of caveolin-1 decreases the levels of
caveolae-associated cathepsin B
To explore further the role of caveolin-1 in the localization of
cathepsin B, we examined the distribution of cathepsin B to
caveolae of control and AS-cav-1 cells. The data revealed that
downregulation of caveolin-1 in AS-cav-1 cells reduced the
association of cathepsin B with caveolae in these cells
compared with control cells (Fig. 2D). Although our previous
work showed that active K-RAS mediated caveolin-1
expression and cathepsin-B localization to caveolae (Cavallo-
Medved et al., 2003), the present data suggest that the
expression of caveolin-1 alone, independent of mutant K-ras,
can also affect the localization of cathepsin B to caveolae of
these cells. This is not surprising, because caveolin-1 is the
main structural protein of caveolae and so downregulation of
caveolin-1 would be expected to reduce the number of caveolae
on the cell surface, as has been previously reported (Cho et al.,
2003; Griffoni et al., 2000). A reduction in caveolae might
contribute to the decrease in cathepsin B associating with these
structures on the cell surface.
Caveolin-1 expression affects the expression and
distribution of p11
The light chain of AIIt, p11, has previously been shown to
bind procathepsin B on the surface of breast cancer and glioma
cells (Mai et al., 2000). Several studies have identified AIIt as
a caveolae-associated protein in various cell types (Harder and
Gerke, 1994; Sargiacomo et al., 1993), including in HCT 116
cells (Cavallo-Medved and Sloane, 2003). Here, we examined
the effects of caveolin-1 production on p11 RNA and protein.
We detected no difference in the p11 RNA levels between
control and AS-cav-1 HCT 116 cells (Fig. 3A) and only
slightly less p11 protein expressed in AS-cav-1 compared with
control cells (Fig. 3B). A more dramatic difference was
observed in the distribution of p11 to caveolae in the two cell
lines. In control cells, p11 was identified in both caveolae and
non-caveolae fractions (Fig. 3C), a pattern also observed in
parental HCT 116 cells (Cavallo-Medved et al., 2003). In AS-
cav-1 cells, however, p11 was not detected in caveolae
fractions and appears to be exclusively isolated in non-
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Fig. 3. Expression and localization of p11 to caveolae are reduced in
AS-cav-1 HCT 116 cells. (A) 1 µl total RNA isolated from control
and AS-cav-1 HCT 116 cells was subjected to reverse transcription
followed by PCR using primer sequences to p11 and β2-
microglobulin (as a control). PCR products were resolved on a 1.2%
agarose gel stained with ethidium bromide. (B) Control and AS-cav-
1 HCT 116 cells were solubilized in lysis buffer containing 1%
Triton X-100 and 60 mM octylglucoside. 25 µg protein were
analysed by SDS-PAGE and immunoblotted with anti-human-p11
antibody. Immunoblots are shown in triplicate and are representative
of at least three experiments. (C) Equal amounts of protein for
control and AS-cav-1 HCT 116 cells were subjected to subcellular
fractionation on a sucrose gradient after homogenization in sodium-
carbonate buffer, pH 11.0. Fractions were collected from the top of
the gradient and equal-volume aliquots of fractions 2-11 were
analysed by SDS-PAGE and immunoblotted with anti-human-p11
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caveolae fractions (Fig. 3C). A similar pattern was
observed in HKh-2 cells (Cavallo-Medved et al., 2003),
a daughter subline of HCT 116 cells in which the mutated
K-ras allele has been deleted by homologous
recombination (Shirasawa et al., 1993). HKh-2 cells,
which are less tumorigenic than HCT 116 cells, were also
shown to produce less caveolin-1 and p11 protein, and to
contain less caveolae-associated cathepsin B and p11 than
HCT 116 cells (Cavallo-Medved et al., 2003). Thus, caveolin-
1 production appears to alter the distribution of p11 to
caveolae, an effect that might contribute to the association of
cathepsin B with caveolae and secretion of the protease from
HCT 116 cells.
Downregulation of caveolin-1 decreases the expression
and alters the distribution of uPA and uPAR
Active cathepsin B in caveolae may be involved in activation
of pro-uPA (Guo, 2002; Ikeda et al., 2000; Kobayashi, 1993).
Our previous study identified pro-uPA and its receptor uPAR
in caveolae of HCT 116 cells, an association that is regulated
by the expression of active K-RAS (Cavallo-Medved et al.,
2003). In this study, we examined the effects of caveolin-1
production on the steady-state levels of uPA and uPAR, and
their associations with caveolae in HCT 116 cells. Although
the intracellular expression levels of mature uPA did appear to
be slightly less in AS-cav-1 cells than in controls (Fig. 4A), we
were unable to detect any mature uPA in the caveolae fractions
of control or AS-cav-1 cells (Fig. 4B), a pattern consistent with
the parental HCT 116 cells (Cavallo-Medved et al., 2003).
Downregulation of caveolin-1 production reduced the levels of
both intracellular and secreted pro-uPA (Fig. 4A). These data
were also consistent with a reduction in the distribution of pro-
uPA to caveolae of AS-cav-1 cells compared with control cells
(Fig. 4B).
Steady-state levels of uPAR were dramatically decreased
following downregulation of caveolin-1 (Fig. 5A). This finding
was further complemented by a striking reduction in the
amount of uPAR in caveolae fractions of AS-cav-1 cells
compared with control cells (Fig. 5B). The downregulation in
uPAR expression and localization to caveolae coincides with
the reduction in the association of pro-uPA with caveolae and
secretion of pro-uPA from AS-cav-1 cells (Fig. 4). In human
articular chondrocytes (Schwab et al., 2001) and kidney 293
cells (Wei et al., 1999), uPAR has been shown to complex with
β1-integrin and caveolin-1. Downregulation of uPAR in HCT
116 cells was shown to disrupt the uPAR/β1-integrin complex
resulting in a fourfold suppression of pro-uPA secretion
(Ahmed et al., 2003). We also examined the expression of
β1-integrin in control versus AS-cav-1 cells and found the
levels to be similar (Fig. 5C). The localization of β1-integrin
specifically to caveolae fractions of AS-cav-1 cells was,
however, reduced compared with control cells (Fig. 5D), a
pattern that resembles that for uPAR (Fig. 5B). Thus, caveolin-
1 expression appears to affect pro-uPA expression and
secretion by mediating uPAR expression and its association
with caveolae and β1-integrin.
Caveolin-1 expression affects the degradation of
collagen IV
We used a well-established fluorescent proteolytic assay
(Sameni et al., 2003) to measure the degradation of collagen-
IV substrate by live colon cancer cells. In this assay, individual
cells are plated on Matrigel containing DQ-collagen IV, a
fluorescently quenched type-IV-collagen substrate, and, over
48 hours, the cells migrate to form spheroids. Degradation of
DQ-collagen IV by the live colon cancer cells and the
accumulation of green fluorescent products were visualized by
confocal microscopy. Both control and AS-cav-1 cells
exhibited intracellular (green punctate pattern within the
spheroid) and pericellular (green ring around the perimeter of
the spheroid) degradation of collagen IV, but the degradation
was dramatically reduced in AS-cav-1 cells compared with
controls (Fig. 6A). Quantification of DQ-collagen IV
degradation was performed using the Metamorph analysis
program and revealed that proteolysis of DQ-collagen IV in
AS-cav-1 cells was approximately half that measured in
control cells (Fig. 6B). Previous studies reported that the lower
levels of uPAR in HKh-2 cells are responsible for these cells
degrading laminin more slowly than HCT 116 cells (Allgayer
et al., 1999). The lower level of uPAR expression in the AS-
cav-1 cells here might similarly affect degradation of collagen-
IV by these cells.
Fig. 4. Expression, secretion and localization of pro-uPA to
caveolae are downregulated in AS-cav-1 HCT 116 cells.
(A) Conditioned media from control and AS-cav-1 HCT 116
cells were collected and the cells were solubilized in lysis
buffer containing 1% Triton X-100, 60 mM octylglucoside.
Media and cell lysates (25 µg protein) were analysed by SDS-
PAGE and immunoblotted with anti-human-uPA antibodies.
Immunoblots are shown in triplicate and are representative of
at least three experiments. (B) Equal amounts of protein for
control and AS-cav-1 HCT 116 cells were subjected to
subcellular fractionation on a sucrose gradient after
homogenization in sodium-carbonate buffer, pH 11.0. Fractions
were collected from the top of the gradient and equal-volume
aliquots of fractions 2-11 were analysed by SDS-PAGE and
immunoblotted with anti-human-uPA antibodies. Immunoblots












Downregulation of caveolin-1 reduces the invasive
potential of colon cancer cells
Type-IV collagen, a component of the basement membrane,
has been shown to be degraded at the invasive edges of tumors
(Zeng et al., 1999). Here, we used Matrigel-invasion assays to
measure the effects of caveolin-1 expression on the invasive
potential of HCT 116 cells. We seeded equal numbers of
control and AS-cav-1 cells on Matrigel-coated filters and
counted the number of cells that had invaded through the
Matrigel after 24 hours. The number of AS-cav-1 cells that
invaded was expressed as a percentage of the number of control
cells that invaded. The Matrigel-invasion assay demonstrated
that the AS-cav-1 cells were ~80% less invasive than control
cells. These data complement the results from the live-cell
proteolysis assays (Fig. 6) and further support a functional role
for caveolin-1, via caveolae-associated proteases and their
receptors, in the invasion and degradation of ECM proteins by
HCT 116 colon cancer cells.
Discussion
Upregulation of proteases and their trafficking to tumor cell
surfaces have been shown to correlate with increased
degradation of ECM proteins during tumor invasion. Many of
the cell-surface proteases that degrade ECM have been
localized to caveolae of cancer cells (Cavallo-Medved and
Sloane, 2003). In the present study, we show that, in human
colorectal carcinoma cells, expression of caveolin-1 (a
structural protein of caveolae) influences the expression of pro-
uPA and its receptor, uPAR, and the localization of cathepsin
B and its receptor, p11. Moreover, our data show that
downregulation of caveolin-1 expression reduces both the
degradation of ECM by these cells and their invasiveness.
Expression and redistribution of active cathepsin B to the
basal plasma membrane during the progression of colon cancer
are associated with a shortened patient survival (Campo et al.,
1994; Hazen et al., 2000). Although the mechanism of cathepsin-
B distribution to the basal plasma membrane remains to be
elucidated, it occurs in late adenomas (Campo et al., 1994)
coincident with the activation of K-ras (Fearon and Vogelstein,
1990). We have shown in our previous studies using HCT 116
human colorectal-carcinoma cells that trafficking of cathepsin B
to caveolae and its secretion is regulated by active K-ras
(Cavallo-Medved et al., 2003). In the present study, we
demonstrate a connection between caveolin-1 production and the
secretion of cathepsin B from HCT 116 cells, suggesting a
functional role for caveolin-1 in the distribution and activity of
this enzyme. One mechanism by which caveolin-1 could affect
cathepsin-B secretion is by mediating its association with
caveolae. Downregulation of caveolin-1 expression in human
umbilical-vein endothelial cells and human diploid fibroblasts
has been shown to reduce the number of cell-surface caveolae
(Cho et al., 2003; Griffoni et al., 2000). Therefore, a decrease in
caveolae-associated cathepsin B in AS-cav-1 HCT 116 cells
might be due to a reduction in the number of caveolae formed
in these cells. Another potential reason for the reduction in
caveolae-associated cathepsin B in AS-cav-1 HCT 116 cells is
the absence of p11 from caveolae of these cells. These results
are consistent with those observed in HKh-2 cells: in this HCT
116 daughter cell line, deletion of K-ras by homologous
recombination results in loss of p11 from caveolae and a
decrease in cathepsin B in the caveolae (Cavallo-Medved et al.,
2003). The light chain subunit of the AIIt, p11, has been found
to bind procathepsin B directly in breast cancer and glioma cells
(Mai et al., 2000). In HCT 116 cells, p11 localizes with both
caveolae-associated cathepsin B and caveolin-1 (Cavallo-
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Fig. 5. Expression and localization
of uPAR and β1-integrin to caveolae
are downregulated in AS-cav-1 HCT
116 cells. (A) Control and AS-cav-1
HCT 116 cells were solubilized in
lysis buffer containing 1% Triton X-
100, 60 mM octylglucoside. 30 µg
protein were analysed by SDS-
PAGE and immunoblotted with anti-
human-uPAR antibodies.
Immunoblots are shown in triplicate
and are representative of at least
three experiments. (B) Equal
amounts of protein for control and
AS-cav-1 HCT 116 cells were
subjected to subcellular fractionation
on a sucrose gradient after
homogenization in sodium-carbonate
buffer, pH 11.0. Fractions were
collected from the top of the gradient
and equal-volume aliquots of
fractions 2-11 were analysed by
SDS-PAGE and immunoblotted with
anti-human-uPAR antibody.
(C) Control and AS-cav-1 HCT 116 cells were solubilized in lysis buffer containing 1% Triton X-100, 60 mM octylglucoside. 20 µg protein
were analysed by SDS-PAGE and immunoblotted with anti-human-β1-integrin antibody. (D) Equal amounts of protein for control and AS-cav-
1 HCT 116 cells were subjected to subcellular fractionation on a sucrose gradient after homogenization in sodium-carbonate buffer, pH 11.0.
Fractions were collected from the top of the gradient and equal-volume aliquots of fractions 2-11 were analysed by SDS-PAGE and
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Medved et al., 2003). Furthermore, p11 has been identified in
caveolae from a range of cells (Cavallo-Medved et al., 2003;
Harder and Gerke, 1994; Sargiacomo et al., 1993).
Colocalization of cathepsin B and p11 to caveolae of colon
cancer cells is intriguing because cathepsin B activates soluble
and membrane-bound pro-uPA (Ikeda et al., 2000; Kobayashi
et al., 1991) and p11 is involved in the binding and activation
of plasminogen (Zhang et al., 2004), events associated with
tumor invasion. Elevated levels of uPA and uPAR in colon
cancer are associated with a negative prognosis (Ganesh et al.,
1994). In colon tumors, overexpression of uPAR is observed at
the invasive edges and enhances tumor invasion and metastasis
(Ganesh et al., 1994). Consistent with these findings, in HKh-
2 cells with disrupted mutant K-ras expression (Allgayer et al.,
1999), localization of uPAR to caveolae is decreased (Cavallo-
Medved et al., 2003). In our present study, we show that
downregulation of caveolin-1 in HCT 116 cells decreases the
expression of uPAR and the expression and secretion of pro-
uPA. Consequently, the levels of caveolae-associated uPAR
and pro-uPA were also reduced in these cells. The dramatic
effects of caveolin-1 on the expression and secretion of pro-
uPA, but not mature uPA, is not surprising because it is the
proenzyme that binds uPAR on the cell surface. uPAR has been
identified in caveolae of several cell types (Cavallo-Medved et
al., 2003; Schwab et al., 2001; Stahl and Mueller, 1995; Wei
et al., 1999). The clustering of uPA and uPAR in caveolae of
human melanoma cells has been shown to enhance the
activation of plasminogen at the cell surface (Stahl and
Mueller, 1995). In human chondrocytes, uPAR forms a
complex with caveolin-1 and β1-integrin (Schwab et al., 2001).
Depletion of caveolin-1 in kidney 293 cells disrupted
uPAR/β1-integrin complexes, resulting in a loss of uPAR-
dependent adhesion and β1-integrin-induced signal
transduction (Wei et al., 1999). A reduction of uPAR
expression in HCT 116 cells has been shown to disrupt
uPAR/β1-integrin complexes without the loss of β1-integrin
expression (Ahmed et al., 2003). Similarly, there was no
change in the overall expression of β1-integrin in AS-cav-1
HCT 116 cells. There was, however, a striking reduction in
caveolae-associated β1-integrin in these cells. The decrease in
caveolin-1 and uPAR expression in AS-cav-1 cells probably
contributes to a loss in uPAR/β1-integrin complexes within
caveolae, leading to the decrease in pro-uPA expression and
secretion, ECM degradation and cell invasion.
uPA is involved in tumor-cell invasion by converting
plasminogen to plasmin, which can either directly degrade
ECM components or activate MMPs. Interestingly, several
MMPs (including MMP-2 and MT1-MMP) have been
localized to caveolae of glioblastomas, fibrosarcomas and
endothelial cells (Annabi et al., 2001; Galvez et al., 2004;
Puyraimond et al., 2001), consistent with the membrane region
facilitating local invasion. Caveolae have also been identified
as a novel pathway for the trafficking of MT1-MMP (MMP-
14) during angiogenesis, regulating the localization, activity
and function of the enzyme in migrating endothelial cells
(Galvez et al., 2004). Nonetheless, we were unable to
demonstrate an effect of caveolin-1 on the expression of MT1-
MMP, MMP-2 or MMP-9 in the HCT 116 cells (data not
shown). In MCF7 breast-carcinoma cells, it has been suggested
that MT1-MMP translocated to caveolae of these cells is
efficiently released from these lipid rafts, a process that is
facilitated by the cytoplasmic tail of the protease (Rozanov et
al., 2004). Perhaps the association of MMPs with caveolae of
HCT 116 cells is also a short-term event, therefore explaining
why we did not observe any differences in AS-cav-1 HCT 116
cells.
Few studies have investigated the link between
caveolae/caveolin-1 and cell-surface proteolysis in cancer. We
hypothesize that caveolae serve as organizing centers for these
enzymes and their receptors in order to modulate proteolytic
events that lead to ECM degradation and invasion. Proteolytic
assays have shown that HCT 116 cells are capable of degrading
type-IV collagen both intracellularly and pericellularly
(Sameni et al., 2003). Moreover, inhibitors of MMPs, plasmin
and cathepsin B reduce the degradation of type-IV collagen by
HCT 116 cells (Sameni et al., 2003). Our results implicate
caveolin-1 in both the intracellular and the pericellular
degradation of type-IV collagen by HCT 116 cells, probably
through regulation of caveolae-associated proteases.
Furthermore, we show a reduction in invasion by AS-cav-1
HCT 116 cells, a pattern previously seen in HKh-2 cells, which
express less caveolin-1 than their HCT 116 parental
counterparts (Sameni et al., 2003).
Caveolin-1 expression has been studied in a wide range of
cancers, although correlations between caveolin-1 and cancer
Fig. 6. Spheroids of live AS-cav-1 HCT 116 cells degrade less DQ-
collagen IV both intracellularly (long arrow) and pericellularly
(arrowhead) than do spheroids of live control HCT 116 cells.
(A) Cells were plated on DQ-collagen-IV/Matrigel-coated coverslips
and imaged at 48 hours. Fluorescent images of DQ-collagen-IV
degradation products (green), taken using an extended depth of
focus, are superimposed on phase images of live spheroids of control
and AS-cav-1 HCT 116 cells. Bar, 10 µm. Images are representative
of at least three experiments. (B) Fluorescent intensity (intracellular
plus pericellular) was measured using Metamorph 6.0 software and is
expressed as average intensity. The graph is representative of at least











remain controversial. Studies in breast cancer have suggested
that caveolin-1 possesses tumor-suppressor activities (for a
review, see Williams and Lisanti, 2004), yet increased
expression of caveolin-1 has been correlated with malignancy
of primary and metastatic prostate (Yang et al., 1998; Yang et
al., 1999), pancreatic (Suzuoki et al., 2002), esophageal
squamous cell (Kato et al., 2002), renal cell (Campbell et al.,
2003) and oral (Hung et al., 2003) carcinomas. In colon
adenocarcinomas, both increases and decreases in expression
of caveolin-1 have been observed (Fine et al., 2001; Bender et
al., 2000). Similar observations have been made in mammary
and lung carcinomas (Lee et al., 1998; Racine et al., 1999;
Yang et al., 1998; Ho et al., 2002). Perhaps caveolin-1 plays
dual roles in tumor development by acting as a tumor
suppressor in early cancers yet as a promoter of metastasis in
late-stage cancers. During early stages of tumorigenesis,
downregulation of caveolin-1 could promote cancer-cell
proliferation and tumor growth, and, as tumors progress,
caveolin-1 production might be induced or increased, thereby
facilitating cell survival and metastasis. Our present studies
using human colorectal-carcinoma cells suggest a regulatory
role for caveolin-1 in the expression, activity and localization
of proteases to the cell surfaces of these cells. These data are
also significant in establishing a functional role for caveolae-
associated proteases in the degradation of ECM proteins during
cancer invasion and metastasis.
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